CPTR Open Forum
Development of Mechanistic/Multiscale/Systems Biology Models in Clinical
Pharmacology and Translational Research:
Do the Challenges Outweigh the Potential Benefits?
7:00 pm ? 9:30 pm on Tuesday, November 16, 2010
During the PSWC 2010 / AAPS Annual Meeting in New Orleans, Louisiana
REGISTER ONLINE at PSWC2010.org.
Multiscale models use data on sub-cellular, paracrine, and endocrine
mechanisms, disease manifestations, pharmacokinetics and pharmacodynamics
of therapeutics, and clinical outcomes to generate simultaneous
predictions of the underlying mechanisms and outcomes of a biologic
system. The goal is to provide a computational workbench that can be used
to explore the ramifications of system perturbations caused by disease
state(s), natural disease progression, aging, genetic abnormalities, and
therapeutic intervention(s). Applied broadly, these models can extend
beyond a single development project to include multiple therapeutic
conditions, thereby instilling rapid, seamless information continuums
across research programs. This will facilitate translational research
efforts by allowing for early in silico exploration while optimizing
experimental and clinical study designs. Still, there exist numerous
rate-limiting steps in the evolution and utilization of these models
including intellectual inertia (delineated by differing discipline
nomenclatures, perspectives, and motivations to develop models), funding,
training, data availability, and compelling examples.
Two brief presentations are planned to provide examples of multiscale
model development and implementation. Panelists will offer academic,
regulatory and industry perspectives to add to an open discussion of the
benefits and challenges we face in moving multiscale modeling forward.
Join us at the 2010 CPTR Open Forum. It promises to be a lively evening of
food, drink, and exchange of scientific ideas.
Session Chair
Matthew Riggs, Ph.D.
Metrum Research Group LLC
Final Agenda
Opening Remarks
Matthew Riggs, Ph.D.
Benefits and Challenges: Model-Driven Drug Development from Target
Identification Through Clinical Development
Matthew Onsum, Ph.D.
Merrimack Pharmaceuticals
Open Panel Discussion